Cue Logo Horizontal.jpg
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
May 10, 2021 08:00 ET | Cue Biopharma, Inc.
And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck...
Cue Logo Horizontal.jpg
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
May 06, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 16, 2021 16:01 ET | Cue Biopharma, Inc.
Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma...
Cue Logo Horizontal.jpg
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
March 15, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma to Host Business Update Call and Webcast
March 09, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
March 01, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
February 25, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
February 22, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Logo Horizontal.jpg
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
February 17, 2021 08:00 ET | Cue Biopharma, Inc.
Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass.,...
Cue Logo Horizontal.jpg
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
February 08, 2021 08:00 ET | Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...